METABOLIC FATE OF ν-(3, 4, 5-TRIMETHOXYPHENYL)-ETHYLAMINE (MESCALINE) IN HUMANS: ISOLATION AND IDENTIFICATION OF 3,4, 5-TRIMETHOXYPHENYLACETIC ACID
Kyriakos Charalampous, A. Orengo, K. Walker, John Kinross-Wright
Journal of Pharmacology and Experimental Therapeutics August 1, 1964 DOI: 10.1016/s0022-3565(25)26849-5 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Population | Human subjects |
| Interventions | β-(3 4 5-trimethoxyphenyl)-ethylamine TMPA |
| Duration | First 12 hours (urine collection period) |
| Topics | Mescaline |
| Key points | After oral administration of labeled β-(3,4,5-trimethoxyphenyl)-ethylamine, humans excreted an average of 81.9% of the dose in urine within 12 hours, with 26.2% as free TMPA. TMPA given orally produced no physiological or psychological changes. |
Abstract
Human subjects given labeled β-(3,4 ,5-trimethoxyphyphenyl) -ethylanoine by mouth excrete an average of 81.9% of the administered dose in the urine during the first 12 hours. An average of 26.2% of the administered dose is excreted in the urine as free TMPA. TMPA given to humans by mouth produces no physiological or psychological changes.